Tr1x, Inc.
🇺🇸United States
Treatment of Moderate to Severe Refractory Crohn's Disease
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Tr1X, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT06721962
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1
Recruiting
- Conditions
- Hematologic MalignancyHematopoietic Stem Cell TransplantAcute Lymphoblastic Leukemia, Adult B-CellAcute Myeloid Leukemia in RemissionCancer RemissionGvHDGVHD, ChronicMyelodysplastic SyndromesGVHD,AcuteAcute Lymphoblastic Leukemia, Adult T-Cell
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Tr1X, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06462365
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath